RecruitingPhase 1/2
NCT06047379Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alo…
United States134 participantsStarted 2023-11-01Updated 2026-07-16 Treatment: NEO212 Oral Capsule, Ipilimumab
RecruitingPhase 1/2
NCT05086692A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of…
United States, Australia +5 more115 participantsStarted 2021-08-27Updated 2025-07-09 Treatment: MDNA11, Pembrolizumab (KEYTRUDA®)